Filana Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2026
Filed with the SEC on May 7, 2026 and accepted by EDGAR at May 7, 2026, 17:16 ET.
Sections
EDGAR did not return this filing’s main document when we asked, so its sections were not extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2026-01-01 to 2026-03-31 | $4.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2026-01-01 to 2026-03-31 | −$11.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2026-01-01 to 2026-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2026-01-01 to 2026-03-31 | −$10.3m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2026-01-01 to 2026-03-31 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months2026-01-01 to 2026-03-31 | −$8.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2026-03-31 | $86.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-03-31 | $88.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2026-03-31 | $108.4m | us-gaap:Assets |
| Current liabilities | At period end2026-03-31 | $40.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2026-03-31 | $40.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2026-03-31 | $68.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-26-015664. Last ingested by Listed: Nov 5, 2026, 16:57 ET. Listed shows no prices and gives no investment advice.